Natixis Advisors, L.P. Neurocrine Biosciences Inc Transaction History
Natixis Advisors, L.P.
- $63 Billion
- Q2 2025
A detailed history of Natixis Advisors, L.P. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Natixis Advisors, L.P. holds 36,392 shares of NBIX stock, worth $4.99 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
36,392
Previous 33,312
9.25%
Holding current value
$4.99 Million
Previous $3.68 Million
24.16%
% of portfolio
0.01%
Previous 0.01%
Shares
24 transactions
Others Institutions Holding NBIX
# of Institutions
655Shares Held
101MCall Options Held
290KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$1.94 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.34 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$763 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$612 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$423 Million0.04% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.1B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...